132 related articles for article (PubMed ID: 36484373)
21. Assessment of Risk Indicators for Targeted Cytomegalovirus Screening in Neonates.
Levit Y; Dym L; Yochpaz S; Manor Y; Adler A; Halutz O; Grisaru-Soen G; Herzlich J; Marom R
Neonatology; 2020; 117(6):750-755. PubMed ID: 33352570
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection.
Hilditch C; Keir AK
Acta Paediatr; 2018 May; 107(5):906. PubMed ID: 29359492
[No Abstract] [Full Text] [Related]
23. First estimates of the potential cost and cost saving of protecting childhood hearing from damage caused by congenital CMV infection.
Williams EJ; Gray J; Luck S; Atkinson C; Embleton ND; Kadambari S; Davis A; Griffiths P; Sharland M; Berrington JE; Clark JE
Arch Dis Child Fetal Neonatal Ed; 2015 Nov; 100(6):F501-6. PubMed ID: 26122458
[TBL] [Abstract][Full Text] [Related]
24. Encouraging postnatal cytomegalovirus (CMV) screening: the time is NOW for universal screening!
Ronchi A; Shimamura M; Malhotra PS; Sánchez PJ
Expert Rev Anti Infect Ther; 2017 May; 15(5):417-419. PubMed ID: 28277819
[No Abstract] [Full Text] [Related]
25. Closer to Universal Newborn Screening for Congenital Cytomegalovirus Infection but Far Away from Antiviral Therapy in All Infected Infants.
Ross S; Long SS; Kimberlin DW
J Pediatr; 2018 Aug; 199():7-9. PubMed ID: 29703574
[No Abstract] [Full Text] [Related]
26. The cost effectiveness of screening newborns for congenital adrenal hyperplasia.
Yoo BK; Grosse SD
Public Health Genomics; 2009; 12(2):67-72. PubMed ID: 19039250
[TBL] [Abstract][Full Text] [Related]
27. Newborn hearing screening: the great omission.
Mehl AL; Thomson V
Pediatrics; 1998 Jan; 101(1):E4. PubMed ID: 9417168
[TBL] [Abstract][Full Text] [Related]
28. Neonates with congenital Cytomegalovirus and hearing loss identified via the universal newborn hearing screening program.
Rawlinson WD; Palasanthiran P; Hall B; Al Yazidi L; Cannon MJ; Cottier C; van Zuylen WJ; Wilkinson M
J Clin Virol; 2018 May; 102():110-115. PubMed ID: 29571077
[TBL] [Abstract][Full Text] [Related]
29. Efficient linking of birth certificate and newborn screening databases for laboratory investigation of congenital cytomegalovirus infection and preterm birth: Florida, 2008.
DePasquale JM; Freeman K; Amin MM; Park S; Rivers S; Hopkins R; Cannon MJ; Dy B; Dollard SC
Matern Child Health J; 2012 Feb; 16(2):486-94. PubMed ID: 21203810
[TBL] [Abstract][Full Text] [Related]
30. [Therapy Options for Infants with Congenital Cytomegalovirus Infection - Implications for Setting Up Neonatal Screening Programs].
Bührer C; Blankenstein O; Rossi R;
Z Geburtshilfe Neonatol; 2020 Apr; 224(2):71-78. PubMed ID: 31426118
[TBL] [Abstract][Full Text] [Related]
31. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
Reischig T; Jindra P; Hes O; Svecová M; Klaboch J; Treska V
Am J Transplant; 2008 Jan; 8(1):69-77. PubMed ID: 17973956
[TBL] [Abstract][Full Text] [Related]
32. Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy.
Faure-Bardon V; Fourgeaud J; Stirnemann J; Leruez-Ville M; Ville Y
Ultrasound Obstet Gynecol; 2021 Oct; 58(4):576-581. PubMed ID: 33998084
[TBL] [Abstract][Full Text] [Related]
33. Evidence based management guidelines for the detection and treatment of congenital CMV.
Kadambari S; Williams EJ; Luck S; Griffiths PD; Sharland M
Early Hum Dev; 2011 Nov; 87(11):723-8. PubMed ID: 21962770
[TBL] [Abstract][Full Text] [Related]
34. Early Identification and Management of Congenital Cytomegalovirus.
Jenks CM; Mithal LB; Hoff SR
Otolaryngol Clin North Am; 2021 Dec; 54(6):1117-1127. PubMed ID: 34535282
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness Analysis of Universal Screening for Biliary Atresia in Japan.
Hoshino E; Moriwaki K; Morimoto K; Sakai K; Shimohata N; Konomura K; Urayama KY; Suzuki M; Shimozuma K
J Pediatr; 2023 Feb; 253():101-106.e2. PubMed ID: 36179888
[TBL] [Abstract][Full Text] [Related]
36. Risk Factors for Congenital Cytomegalovirus Infection Following Primary and Nonprimary Maternal Infection: A Prospective Neonatal Screening Study Using Polymerase Chain Reaction in Saliva.
Leruez-Ville M; Magny JF; Couderc S; Pichon C; Parodi M; Bussières L; Guilleminot T; Ghout I; Ville Y
Clin Infect Dis; 2017 Aug; 65(3):398-404. PubMed ID: 28419213
[TBL] [Abstract][Full Text] [Related]
37. Oral valganciclovir treatment for congenital cytomegalovirus infection.
Imamura T; Suzutani T; Ogawa H; Asano K; Nomoto M; Matsui T; Momoi N; Ikuta K; Inoue N; Hosoya M
Pediatr Int; 2011 Apr; 53(2):249-52. PubMed ID: 21501311
[No Abstract] [Full Text] [Related]
38. Screening for seemingly healthy newborns with congenital cytomegalovirus infection by quantitative real-time polymerase chain reaction using newborn urine: an observational study.
Yamaguchi A; Oh-Ishi T; Arai T; Sakata H; Adachi N; Asanuma S; Oguma E; Kimoto H; Matsumoto J; Fujita H; Uesato T; Fujita J; Shirato K; Ohno H; Kizaki T
BMJ Open; 2017 Jan; 7(1):e013810. PubMed ID: 28110288
[TBL] [Abstract][Full Text] [Related]
39. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
[TBL] [Abstract][Full Text] [Related]
40. Congenital Cytomegalovirus Targeted Screening Implementation and Outcomes: A Retrospective Chart Review.
Ronner EA; Glovsky CK; Herrmann BS; Woythaler MA; Pasternack MS; Cohen MS
Otolaryngol Head Neck Surg; 2022 Jul; 167(1):178-182. PubMed ID: 34520270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
